Edition:
India

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

259.90CHF
15 Dec 2017
Change (% chg)

CHF-4.80 (-1.81%)
Prev Close
CHF264.70
Open
CHF265.70
Day's High
CHF265.90
Day's Low
CHF259.90
Volume
663,613
Avg. Vol
304,937
52-wk High
CHF270.80
52-wk Low
CHF150.80

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 0.99
Market Cap(Mil.): CHF19,317.19
Shares Outstanding(Mil.): 74.47
Dividend: 2.55
Yield (%): 0.98

Financials

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

02 Nov 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

03 Oct 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

03 Oct 2017

UPDATE 1-Lonza confirms 2017 outlook, outlines new 2022 targets

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG confirmed its 2017 outlook on Wednesday and outlined new targets through 2022.

26 Jul 2017

Lonza confirms 2017 outlook, outlines new 2022 targets

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG on Wednesday confirmed its 2017 outlook and outlined new targets through to 2022.

26 Jul 2017

BRIEF-Lonza H1 sales 15.1 percent up to CHF 2,323 million

* Lonza delivers strong performance in first half 2017 and sets a strong foundation for continued attractive mid-term growth

26 Jul 2017

BRIEF-Lonza says received regulatory approval for Capsugel acquisition

* Says lonza has received all regulatory approvals to move forward with acquisition of Capsugel

27 Jun 2017

Earnings vs. Estimates